<p>Pharmaceutical company Merck said Friday that in a final analysis of a clinical trial, its antiviral pill reduced the risk of hospitalization and death among high-risk Covid-19 patients by 30 per cent, down from an earlier estimate of 50 per cent.</p>.<p>The lower efficacy is a disappointment for the drug, known as molnupiravir, which health officials around the world are counting on as a critical tool to save lives and reduce the burden on hospitals. It increases the importance of a similar, apparently more effective, offering from Pfizer that is also under review by the Food and Drug Administration.</p>.<p>A panel of advisers to the FDA is set to meet Tuesday to discuss Merck’s treatment and vote on whether to recommend authorizing it to treat high-risk Covid-19 patients.</p>.<p>In briefing documents posted to the FDA’s website Friday, agency reviewers did not take a position on whether the drug should be authorized, although they found that the clinical trial data did not show any major safety concerns and that the drug was effective in preventing severe disease.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/international/who-designates-new-covid-strain-as-variant-of-concern-names-it-omicron-1055010.html" target="_blank">WHO designates new Covid strain as 'variant of concern', names it Omicron</a></strong></p>.<p>The reviewers said they had only become aware of the updated efficacy estimate earlier this week and were still reviewing the data. They said they could update their assessment when the panel meets Tuesday.</p>.<p>Merck’s initial estimate that the drug reduced hospitalization and death by 50 per cent came from an early look at results from 775 study participants. The updated figure announced Friday came from more than 1,400. In the final analysis, the participants who received molnupiravir had a 6.8 per cent risk of being hospitalized, and one patient died. Those who received a placebo had a 9.7 per cent risk of being hospitalized, and nine died.</p>.<p>Dr. David Boulware, an infectious disease researcher at the University of Minnesota, said he expected the drug would still receive emergency authorization. If the expert committee endorses it and the FDA heeds the recommendation, the treatment could be authorized in the United States as soon as next week.</p>.<p>Pfizer’s antiviral pill, Paxlovid, which was found in a clinical trial to cut the risk of hospitalization and death by 89 per cent, could become available within weeks.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>
<p>Pharmaceutical company Merck said Friday that in a final analysis of a clinical trial, its antiviral pill reduced the risk of hospitalization and death among high-risk Covid-19 patients by 30 per cent, down from an earlier estimate of 50 per cent.</p>.<p>The lower efficacy is a disappointment for the drug, known as molnupiravir, which health officials around the world are counting on as a critical tool to save lives and reduce the burden on hospitals. It increases the importance of a similar, apparently more effective, offering from Pfizer that is also under review by the Food and Drug Administration.</p>.<p>A panel of advisers to the FDA is set to meet Tuesday to discuss Merck’s treatment and vote on whether to recommend authorizing it to treat high-risk Covid-19 patients.</p>.<p>In briefing documents posted to the FDA’s website Friday, agency reviewers did not take a position on whether the drug should be authorized, although they found that the clinical trial data did not show any major safety concerns and that the drug was effective in preventing severe disease.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/international/who-designates-new-covid-strain-as-variant-of-concern-names-it-omicron-1055010.html" target="_blank">WHO designates new Covid strain as 'variant of concern', names it Omicron</a></strong></p>.<p>The reviewers said they had only become aware of the updated efficacy estimate earlier this week and were still reviewing the data. They said they could update their assessment when the panel meets Tuesday.</p>.<p>Merck’s initial estimate that the drug reduced hospitalization and death by 50 per cent came from an early look at results from 775 study participants. The updated figure announced Friday came from more than 1,400. In the final analysis, the participants who received molnupiravir had a 6.8 per cent risk of being hospitalized, and one patient died. Those who received a placebo had a 9.7 per cent risk of being hospitalized, and nine died.</p>.<p>Dr. David Boulware, an infectious disease researcher at the University of Minnesota, said he expected the drug would still receive emergency authorization. If the expert committee endorses it and the FDA heeds the recommendation, the treatment could be authorized in the United States as soon as next week.</p>.<p>Pfizer’s antiviral pill, Paxlovid, which was found in a clinical trial to cut the risk of hospitalization and death by 89 per cent, could become available within weeks.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>